Zedxr Tablet SR is a sustained-release oral antidiabetic medication containing a combination of Gliclazide 80mg and Metformin 500mg. This formulation is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy. Gliclazide, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Zedxr Tablet SR should be used as part of a comprehensive diabetes management plan, including diet and lifestyle modifications. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose levels, renal function, and potential adverse effects is essential during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Patients should be advised to adhere strictly to prescribed dosing schedules and report any signs of hypoglycemia or gastrointestinal discomfort promptly.